Genetically engineered human trophoblast cells, methods of making and using the same
By co-expressing mbIL-21, CD137L, and DLL1 in K562 cells, the JY511 cell line was constructed, which solved the problems of low expansion efficiency and poor functional maintenance of NK cells and γδ T cells in the existing technology, and achieved efficient expansion and safe cell therapy support, which is suitable for GMP and industrial production.
CN122128247BActive Publication Date: 2026-07-24HANGZHOU JIYUAN GENE TECH CO LTD
View PDF 2 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HANGZHOU JIYUAN GENE TECH CO LTD
- Filing Date
- 2026-04-30
- Publication Date
- 2026-07-24
Smart Images
Figure CN122128247B_ABST
Abstract
The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.
Need to check novelty before this filing date? Find Prior Art